MOMENTA PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.momentapharma.com
Clinical Trials
37
Active:25
Completed:9
Trial Phases
3 Phases
Phase 1:30
Phase 2:4
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
Phase 1
30 (83.3%)Phase 2
4 (11.1%)Phase 3
2 (5.6%)An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03896295
- Locations
- 🇬🇧
Momenta Investigational Site, Sheffield, United Kingdom
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
Phase 1
Terminated
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03866577
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Oncology Institute of Hope and Innovation, Whittier, California, United States
🇺🇸Lakes Research, Miami Lakes, Florida, United States
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT03772587
- Locations
- 🇬🇧
Momenta Investigational Site, Southampton, United Kingdom
Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 243
- Registration Number
- NCT02923583
- Locations
- 🇬🇧
Covance Clincal Research Unit Ltd, Leeds, United Kingdom
🇬🇧Hammersmith Medicines Research (HMR), London, United Kingdom
An Ascending Dose Study to Evaluate M281 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02828046
- Locations
- 🇳🇱
PRA Health Sciences, Zuidlaren, Netherlands
- Prev
- 1
- 2
- Next
News
No news found